The Institute for International Cooperation in Animal Biologics (IICAB) announced that registration for the Veterinary Biologics Training Program, to be held May 20-24, is now open through April 15. If space is available, late applications will be accepted.

IICAB said the Veterinary Biologics Training Program provides an overview of the U.S. Department of Agriculture's regulatory process for assuring the purity, safety, potency and efficacy of veterinary biologics (vaccines, bacterins, antisera, diagnostic kits and other products of biological origin).

Representatives from the Center for Veterinary Biologics (CVB) of USDA's Animal & Plant Health Inspection Service present information on the requirements and processes for licensing/registration and testing of veterinary biological products, IICAB said. The inspection and compliance process for production, release and post-marketing surveillance of veterinary biological products is also covered in both lectures and workshops.

According to the announcement, professionals working in the veterinary biologics industry, researchers developing biologics and regulatory personnel are encouraged to attend and learn about current CVB requirements.

The program is organized by IICAB and is co-sponsored by CVB and the Iowa State University College of Veterinary Medicine.

Detailed information, including the daily itinerary, registration deadlines and fees, meals, transportation and lodging, can be found at www.cfsph.iastate.edu/IICAB/meetings/may2019.php. Participants can register for a single day or the entire program.

In 2018, the program was approved for 30.5 hours of continuing education for veterinarians or veterinary technicians in jurisdictions that recognize AAVSB RACE approval, IICAB said, noting that AAVSB RACE approval will be requested for the May 2019 program.

IICAB also offers several online courses covering the field of immunology. Additional information can be found at www.cfsph.iastate.edu/Immunology.

Source: Institute for International Cooperation in Animal Biologics, which is solely responsible for the information provided and is wholly owned by the source. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.